Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Just Gave Pancreatic Cancer Patients Early Access To A Pill That Doubled Survival Time

The Food and Drug Administration has authorized early expanded access to a new pill called daraxonrasib, developed by Revolution Medicines, giving patients with advanced pancreatic cancer a chance to receive the experimental treatment while it awaits full regulatory approval, in a move the agency completed just two days after receiving the request. Pancreatic cancer is among the most lethal cancers in existence, with a five-year survival rate of only about 3 percent for the most common metastatic form, and until now new treatment options have been frustratingly scarce for patients who have already tried conventional therapies. The speed of the FDA’s response was itself notable: the regulator received Revolution Medicines’ expanded access application on April 28th and signed it on April 30th, and the FDA Commissioner said the two-day turnaround reflects the agency’s commitment to getting promising treatments to patients with life-threatening conditions without delay. The pill works by targeting a protein called RAS, which is mutated in the majority of pancreatic cancer tumors and had for decades been considered essentially undruggable.

In a closely watched phase 3 trial called RASolute 302, daraxonrasib produced results the oncology community called unprecedented: patients taking the pill survived a median of 13.2 months compared to 6.7 months for those receiving standard chemotherapy, a 60 percent reduction in the risk of death. The drug is taken orally once a day and was generally well tolerated in the trial, with no new safety signals reported. Daraxonrasib has also received Breakthrough Therapy and Orphan Drug designations from the FDA, and the company says it intends to submit a full new drug application under the FDA’s national priority program. Revolution Medicines said it is moving as quickly as possible to ensure safe and equitable access to the drug for eligible patients across the United States.

Source: https://www.reuters.com/legal/litigation/us-fda-authorizes-early-access-revolutions-pancreatic-cancer-pill-2026-05-01/

PrevPreviousCommunities Across America Are Banning AI Data Centers And The Number Just Jumped From 8 To 78
NextA Kitten Found Covered Head To Tail In Industrial Glue Just Made A Full Recovery And Has A New HomeNext

Recent Articles

Happy News

Eating Eggs Regularly May Cut Alzheimers Risk By Up To 27 Percent

May 9, 2026

A new study from Loma Linda University Health has found that adults 65 and older who eat eggs regularly have a significantly lower risk of developing Alzheimer’s disease, with people who consumed at least one egg per day for five or more days a week showing up to a 27

Read More
Happy News

Birdwatching Among Gen Z In Britain Has Grown By Over 1000 Percent Since 2018 And The Reasons Why Are Beautiful

May 8, 2026

Birdwatching has quietly become one of the fastest-growing hobbies among young people in Britain, with new research from the Royal Society for the Protection of Birds finding that nearly 750,000 people aged 16 to 29 now birdwatch regularly, a staggering increase of more than 1,000 percent since 2018. The study

Read More
Happy News

Meet The Record Holders Who Prove That Age Is Genuinely Just A Number

May 8, 2026

Guinness World Records has published a new feature celebrating some of the most extraordinary older athletes on the planet, a collection of record holders that makes a compelling case that age really is just a number. Leading the group is Mathea Allansmith of Hawaii, born in 1930, who took up

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.